National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology , Wuhan 430074, P. R. China.
Wuhan Institute of Biotechnology , High Tech Road 666, East Lake High Tech Zone, Wuhan 430040, P. R. China.
ACS Appl Mater Interfaces. 2017 Dec 6;9(48):42225-42238. doi: 10.1021/acsami.7b14796. Epub 2017 Nov 20.
Selective drug release is highly desirable for photothermal/chemo combination therapy when two or even more theranostic agents are encapsulated together within the same nanocarrier. A conventional nanocarrier can hardly achieve this goal. Herein, doxorubicin and indocyanine green (DOX/ICG)-loaded nanocolloidosomes (NCs), with selective drug release, were fabricated as a novel multifunctional theranostic nanoplatform for photothermal/chemo combination therapy. Templating from galactose-functionalized hydroxyethyl starch-polycaprolactone (Gal-HES-PCL) nanoparticles-stabilized Pickering emulsions, the resultant DOX/ICG@Gal-HES-PCL NCs had a diameter of around 140 nm and showed an outstanding tumor-targeting ability, preferable tumor penetration capability, and promotion of photothermal effect. Moreover, these NCs can be used for NIR fluorescence imaging and thus render real-time imaging of solid tumors with high contrast. Collectively, such NCs achieved the best in vivo antitumor efficacy combined with laser irradiation compared with DOX/ICG@HES-PCL NCs and DOX/ICG mixture. These NCs are valuable for active tumor-targeted imaging-guided combination therapy against liver cancer and potentially other diseases.
当两种甚至更多治疗剂被封装在同一个纳米载体中时,光热/化疗联合治疗非常需要选择性药物释放。传统的纳米载体很难实现这一目标。在此,我们制备了载有阿霉素和吲哚菁绿(DOX/ICG)的纳米胶束(NCs),作为一种新型多功能光热/化疗联合治疗的治疗性纳米平台,具有选择性药物释放。通过半乳糖功能化羟乙基淀粉-聚己内酯(Gal-HES-PCL)纳米粒子稳定的Pickering 乳液模板化,得到的 DOX/ICG@Gal-HES-PCL NCs 的直径约为 140nm,表现出优异的肿瘤靶向能力、良好的肿瘤穿透能力和促进光热效应。此外,这些 NCs 可用于近红外荧光成像,从而实现高对比度的实体瘤实时成像。总的来说,与 DOX/ICG@HES-PCL NCs 和 DOX/ICG 混合物相比,这些 NCs 在激光照射下具有最佳的体内抗肿瘤疗效。这些 NCs 对于针对肝癌和其他潜在疾病的主动肿瘤靶向成像引导联合治疗具有重要价值。
ACS Appl Mater Interfaces. 2017-11-20
ACS Omega. 2025-5-30
Int J Nanomedicine. 2025-5-7
Adv Sci (Weinh). 2024-7
Pharmaceuticals (Basel). 2024-2-27